Lam Paul K Y, Ho W K, Ng Manwa L, Wei William I
Division of Otorhinolaryngology, Head & Neck Surgery, Department of Surgery, University of Hong Kong Medical Centre, Queen Mary Hospital, Hong Kong.
Otolaryngol Head Neck Surg. 2007 Mar;136(3):440-4. doi: 10.1016/j.otohns.2006.11.009.
To justify the application of medialization thyroplasty in Chinese patients with symptomatic cancer-related unilateral vocal fold paralysis (UVFP).
Retrospective chart review from February 2000 to March 2006.
Eighty-seven Chinese patients undergoing medialization thyroplasty for UVFP were included; there were no significant differences between the cancer-related and benign groups in terms of the speech and swallowing rehabilitation outcome and the perioperative complication rate (P > 0.05). The median survival time of cancer-related UVFP patients from the date of medialization to death was 129 days. Age more than 65 years was identified as the only factor for a shorter survival period after medialization (P = 0.040).
Medialization thyroplasty restores satisfactory speech and swallowing and has a low perioperative complication rate in Chinese patients with cancer-related UVFP. Postmedialization survival period was also reasonable.
Medialization thyroplasty is a justifiable treatment option for cancer-related UVFP.
论证喉内移术在中国有症状的癌症相关性单侧声带麻痹(UVFP)患者中的应用合理性。
回顾性病历分析,时间跨度为2000年2月至2006年3月。
纳入87例行喉内移术治疗UVFP的中国患者;癌症相关性组与良性组在言语和吞咽功能康复结局及围手术期并发症发生率方面无显著差异(P>0.05)。癌症相关性UVFP患者从喉内移术日期至死亡的中位生存时间为129天。年龄大于65岁被确定为喉内移术后生存期较短的唯一因素(P=0.040)。
对于中国癌症相关性UVFP患者,喉内移术可恢复令人满意的言语和吞咽功能,围手术期并发症发生率低。喉内移术后生存期也较为合理。
喉内移术是癌症相关性UVFP的合理治疗选择。